Journal article
Validation of the prognostic performance of Breast Cancer Index (BCI) in hormone receptor-positive (HR+) postmenopausal breast cancer patients in the TEAM trial
Abstract
PURPOSE: Patients with early-stage hormone receptor-positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0-10 years) and late (5-10 years) distant recurrence (DR) risk in N0 and N1 patients. Here, BCI prognostic performance was evaluated in HR+ postmenopausal women from the Tamoxifen and Exemestane Adjuvant Multinational …
Authors
Bartlett JMS; Xu K; Wong J; Pond G; Zhang Y; Spears M; Salunga R; Mallon E; Taylor KJ; Hasenburg A
Journal
Clinical Cancer Research, Vol. 30, No. 8, pp. 1509–1517
Publisher
American Association for Cancer Research (AACR)
Publication Date
April 15, 2024
DOI
10.1158/1078-0432.ccr-23-2436
ISSN
1078-0432